CAR-NK cell therapy in multiple myeloma: from preclinical and clinical landscape to joining the force for treatment strategies optimization Article Swipe
Gelayol Asadi
,
Ahmad Gharehbaghian
,
Saeid Abroun
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1186/s12964-025-02443-1
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1186/s12964-025-02443-1
Natural killer (NK) cells are specialized components of the innate immune system with an essential role in immune surveillance against multiple myeloma (MM). However, patients with MM often exhibit significant impairments in both the quantity and functionality of NK cells, particularly those who are refractory or have relapsed disease. Increasing evidence suggests that harnessing NK cells may provide a promising "off-the-shelf" therapeutic strategy for treating MM. Recent advancements in chimeric antigen receptor (CAR) engineering have enhanced the capabilities of NK cells, allowing them to target MM-associated antigens effectively. This innovative approach may help mitigate the off-target toxicities often associated with NK cells and address challenges such as the ability of MM cells to evade immune detection. CAR-NK therapy shows promise for B-cell malignancies, but its efficacy in MM has been less examined. This comprehensive review revealed that CAR-NK cells elicit a robust immune response against myeloma cells in preclinical studies conducted both in vitro and in vivo. Furthermore, the development of dual-CAR NK cell therapies indicates promise in overcoming myeloma escape mechanisms. Numerous clinical trials are currently underway to evaluate the efficacy and safety of CAR-NK cell therapy for individuals diagnosed with MM.
Related Topics
Concepts
No concepts available.
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1186/s12964-025-02443-1
- OA Status
- gold
- Cited By
- 1
- References
- 307
- OpenAlex ID
- https://openalex.org/W4416122378
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4416122378Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1186/s12964-025-02443-1Digital Object Identifier
- Title
-
CAR-NK cell therapy in multiple myeloma: from preclinical and clinical landscape to joining the force for treatment strategies optimizationWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-11-11Full publication date if available
- Authors
-
Gelayol Asadi, Ahmad Gharehbaghian, Saeid AbrounList of authors in order
- Landing page
-
https://doi.org/10.1186/s12964-025-02443-1Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1186/s12964-025-02443-1Direct OA link when available
- Cited by
-
1Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 1Per-year citation counts (last 5 years)
- References (count)
-
307Number of works referenced by this work
Full payload
| id | https://openalex.org/W4416122378 |
|---|---|
| doi | https://doi.org/10.1186/s12964-025-02443-1 |
| ids.doi | https://doi.org/10.1186/s12964-025-02443-1 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/41219881 |
| ids.openalex | https://openalex.org/W4416122378 |
| fwci | 0.0 |
| mesh[0].qualifier_ui | Q000628 |
| mesh[0].descriptor_ui | D009101 |
| mesh[0].is_major_topic | True |
| mesh[0].qualifier_name | therapy |
| mesh[0].descriptor_name | Multiple Myeloma |
| mesh[1].qualifier_ui | Q000276 |
| mesh[1].descriptor_ui | D009101 |
| mesh[1].is_major_topic | True |
| mesh[1].qualifier_name | immunology |
| mesh[1].descriptor_name | Multiple Myeloma |
| mesh[2].qualifier_ui | |
| mesh[2].descriptor_ui | D006801 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | |
| mesh[2].descriptor_name | Humans |
| mesh[3].qualifier_ui | Q000276 |
| mesh[3].descriptor_ui | D007694 |
| mesh[3].is_major_topic | True |
| mesh[3].qualifier_name | immunology |
| mesh[3].descriptor_name | Killer Cells, Natural |
| mesh[4].qualifier_ui | Q000378 |
| mesh[4].descriptor_ui | D000076962 |
| mesh[4].is_major_topic | True |
| mesh[4].qualifier_name | metabolism |
| mesh[4].descriptor_name | Receptors, Chimeric Antigen |
| mesh[5].qualifier_ui | Q000276 |
| mesh[5].descriptor_ui | D000076962 |
| mesh[5].is_major_topic | True |
| mesh[5].qualifier_name | immunology |
| mesh[5].descriptor_name | Receptors, Chimeric Antigen |
| mesh[6].qualifier_ui | |
| mesh[6].descriptor_ui | D000818 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | |
| mesh[6].descriptor_name | Animals |
| mesh[7].qualifier_ui | Q000379 |
| mesh[7].descriptor_ui | D016219 |
| mesh[7].is_major_topic | True |
| mesh[7].qualifier_name | methods |
| mesh[7].descriptor_name | Immunotherapy, Adoptive |
| mesh[8].qualifier_ui | Q000628 |
| mesh[8].descriptor_ui | D009101 |
| mesh[8].is_major_topic | True |
| mesh[8].qualifier_name | therapy |
| mesh[8].descriptor_name | Multiple Myeloma |
| mesh[9].qualifier_ui | Q000276 |
| mesh[9].descriptor_ui | D009101 |
| mesh[9].is_major_topic | True |
| mesh[9].qualifier_name | immunology |
| mesh[9].descriptor_name | Multiple Myeloma |
| mesh[10].qualifier_ui | |
| mesh[10].descriptor_ui | D006801 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | |
| mesh[10].descriptor_name | Humans |
| mesh[11].qualifier_ui | Q000276 |
| mesh[11].descriptor_ui | D007694 |
| mesh[11].is_major_topic | True |
| mesh[11].qualifier_name | immunology |
| mesh[11].descriptor_name | Killer Cells, Natural |
| mesh[12].qualifier_ui | Q000378 |
| mesh[12].descriptor_ui | D000076962 |
| mesh[12].is_major_topic | True |
| mesh[12].qualifier_name | metabolism |
| mesh[12].descriptor_name | Receptors, Chimeric Antigen |
| mesh[13].qualifier_ui | Q000276 |
| mesh[13].descriptor_ui | D000076962 |
| mesh[13].is_major_topic | True |
| mesh[13].qualifier_name | immunology |
| mesh[13].descriptor_name | Receptors, Chimeric Antigen |
| mesh[14].qualifier_ui | |
| mesh[14].descriptor_ui | D000818 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | |
| mesh[14].descriptor_name | Animals |
| mesh[15].qualifier_ui | Q000379 |
| mesh[15].descriptor_ui | D016219 |
| mesh[15].is_major_topic | True |
| mesh[15].qualifier_name | methods |
| mesh[15].descriptor_name | Immunotherapy, Adoptive |
| type | article |
| title | CAR-NK cell therapy in multiple myeloma: from preclinical and clinical landscape to joining the force for treatment strategies optimization |
| biblio.issue | 1 |
| biblio.volume | 23 |
| biblio.last_page | 485 |
| biblio.first_page | 485 |
| is_xpac | False |
| apc_list.value | 2390 |
| apc_list.currency | GBP |
| apc_list.value_usd | 2931 |
| apc_paid.value | 2390 |
| apc_paid.currency | GBP |
| apc_paid.value_usd | 2931 |
| language | en |
| locations[0].id | doi:10.1186/s12964-025-02443-1 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S138104925 |
| locations[0].source.issn | 1478-811X |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 1478-811X |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Cell Communication and Signaling |
| locations[0].source.host_organization | https://openalex.org/P4310320256 |
| locations[0].source.host_organization_name | BioMed Central |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320256 |
| locations[0].license | |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Cell Communication and Signaling |
| locations[0].landing_page_url | https://doi.org/10.1186/s12964-025-02443-1 |
| locations[1].id | pmid:41219881 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Cell communication and signaling : CCS |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/41219881 |
| locations[2].id | pmh:oai:doaj.org/article:3e73b0d3d8b44fa8ab701a9ba4fec47e |
| locations[2].is_oa | False |
| locations[2].source.id | https://openalex.org/S4306401280 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[2].source.host_organization | |
| locations[2].source.host_organization_name | |
| locations[2].source.host_organization_lineage | |
| locations[2].license | |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | article |
| locations[2].license_id | |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Cell Communication and Signaling, Vol 23, Iss 1, Pp 1-34 (2025) |
| locations[2].landing_page_url | https://doaj.org/article/3e73b0d3d8b44fa8ab701a9ba4fec47e |
| locations[3].id | pmh:oai:europepmc.org:11418243 |
| locations[3].is_oa | True |
| locations[3].source.id | https://openalex.org/S4306400806 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | Europe PMC (PubMed Central) |
| locations[3].source.host_organization | https://openalex.org/I1303153112 |
| locations[3].source.host_organization_name | European Bioinformatics Institute |
| locations[3].source.host_organization_lineage | https://openalex.org/I1303153112 |
| locations[3].license | other-oa |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | Text |
| locations[3].license_id | https://openalex.org/licenses/other-oa |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | |
| locations[3].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/12606997 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5078550889 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-7197-541X |
| authorships[0].author.display_name | Gelayol Asadi |
| authorships[0].countries | IR |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I1516879 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran |
| authorships[0].institutions[0].id | https://openalex.org/I1516879 |
| authorships[0].institutions[0].ror | https://ror.org/03mwgfy56 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I1516879 |
| authorships[0].institutions[0].country_code | IR |
| authorships[0].institutions[0].display_name | Tarbiat Modares University |
| authorships[0].author_position | middle |
| authorships[0].raw_author_name | Gelayol Asadi |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran |
| authorships[1].author.id | https://openalex.org/A5101514872 |
| authorships[1].author.orcid | https://orcid.org/0000-0003-4265-585X |
| authorships[1].author.display_name | Ahmad Gharehbaghian |
| authorships[1].countries | IR |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I58048189 |
| authorships[1].affiliations[0].raw_affiliation_string | Laboratory Hematology and Blood Bank Department, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran |
| authorships[1].institutions[0].id | https://openalex.org/I58048189 |
| authorships[1].institutions[0].ror | https://ror.org/034m2b326 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I58048189 |
| authorships[1].institutions[0].country_code | IR |
| authorships[1].institutions[0].display_name | Shahid Beheshti University of Medical Sciences |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Ahmad Gharehbaghian |
| authorships[1].is_corresponding | True |
| authorships[1].raw_affiliation_strings | Laboratory Hematology and Blood Bank Department, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran |
| authorships[2].author.id | https://openalex.org/A5047570182 |
| authorships[2].author.orcid | https://orcid.org/0000-0001-9459-4994 |
| authorships[2].author.display_name | Saeid Abroun |
| authorships[2].countries | IR |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I1516879 |
| authorships[2].affiliations[0].raw_affiliation_string | Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran |
| authorships[2].institutions[0].id | https://openalex.org/I1516879 |
| authorships[2].institutions[0].ror | https://ror.org/03mwgfy56 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I1516879 |
| authorships[2].institutions[0].country_code | IR |
| authorships[2].institutions[0].display_name | Tarbiat Modares University |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Saeid Abroun |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1186/s12964-025-02443-1 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-11-11T00:00:00 |
| display_name | CAR-NK cell therapy in multiple myeloma: from preclinical and clinical landscape to joining the force for treatment strategies optimization |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-28T05:39:59.997338 |
| primary_topic | |
| cited_by_count | 1 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 1 |
| locations_count | 4 |
| best_oa_location.id | doi:10.1186/s12964-025-02443-1 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S138104925 |
| best_oa_location.source.issn | 1478-811X |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 1478-811X |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Cell Communication and Signaling |
| best_oa_location.source.host_organization | https://openalex.org/P4310320256 |
| best_oa_location.source.host_organization_name | BioMed Central |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320256 |
| best_oa_location.license | |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Cell Communication and Signaling |
| best_oa_location.landing_page_url | https://doi.org/10.1186/s12964-025-02443-1 |
| primary_location.id | doi:10.1186/s12964-025-02443-1 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S138104925 |
| primary_location.source.issn | 1478-811X |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 1478-811X |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Cell Communication and Signaling |
| primary_location.source.host_organization | https://openalex.org/P4310320256 |
| primary_location.source.host_organization_name | BioMed Central |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320256 |
| primary_location.license | |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Cell Communication and Signaling |
| primary_location.landing_page_url | https://doi.org/10.1186/s12964-025-02443-1 |
| publication_date | 2025-11-11 |
| publication_year | 2025 |
| referenced_works | https://openalex.org/W3116064748, https://openalex.org/W4400094382, https://openalex.org/W4366975166, https://openalex.org/W2772248651, https://openalex.org/W3107664641, https://openalex.org/W2995373288, https://openalex.org/W4404310617, https://openalex.org/W4206541189, https://openalex.org/W3198558595, https://openalex.org/W4389246785, https://openalex.org/W2137040543, https://openalex.org/W2160088903, https://openalex.org/W2095109341, https://openalex.org/W2063355387, https://openalex.org/W1997686829, https://openalex.org/W1484502710, https://openalex.org/W1884682701, https://openalex.org/W1989706630, https://openalex.org/W2144728882, https://openalex.org/W4285299761, https://openalex.org/W4392356425, https://openalex.org/W4389259284, https://openalex.org/W4400206773, https://openalex.org/W3136561855, https://openalex.org/W4404112993, https://openalex.org/W2134640078, https://openalex.org/W4389220423, https://openalex.org/W4385903393, https://openalex.org/W2902700677, https://openalex.org/W4392739819, https://openalex.org/W1972525178, https://openalex.org/W2982678407, https://openalex.org/W4205539774, https://openalex.org/W4309243005, https://openalex.org/W2135688355, https://openalex.org/W3106584660, https://openalex.org/W4282962191, https://openalex.org/W3006655689, https://openalex.org/W3178434074, https://openalex.org/W3176532045, https://openalex.org/W2885605094, https://openalex.org/W2756061744, https://openalex.org/W2066492659, https://openalex.org/W2050209022, https://openalex.org/W2154179430, https://openalex.org/W2011363188, https://openalex.org/W2335809174, https://openalex.org/W2026884886, https://openalex.org/W2073300038, https://openalex.org/W1969814796, https://openalex.org/W1969950463, https://openalex.org/W2768639020, https://openalex.org/W1873760231, https://openalex.org/W3085645144, https://openalex.org/W2020973179, https://openalex.org/W2004373794, https://openalex.org/W2079786360, https://openalex.org/W1570463153, https://openalex.org/W2939811893, https://openalex.org/W1562270544, https://openalex.org/W2116171543, https://openalex.org/W2891691090, https://openalex.org/W1900016038, https://openalex.org/W2084292672, https://openalex.org/W1481809543, https://openalex.org/W1992508362, https://openalex.org/W2944519468, https://openalex.org/W1972529519, https://openalex.org/W2902074696, https://openalex.org/W3012031746, https://openalex.org/W3044976615, https://openalex.org/W2064449233, https://openalex.org/W1976229112, https://openalex.org/W2118182005, https://openalex.org/W2095828046, https://openalex.org/W1981352048, https://openalex.org/W2070551124, https://openalex.org/W2403400382, https://openalex.org/W2580088419, https://openalex.org/W1996032846, https://openalex.org/W1971408711, https://openalex.org/W2152105313, https://openalex.org/W1997849135, https://openalex.org/W2177971463, https://openalex.org/W1971411560, https://openalex.org/W3043781639, https://openalex.org/W4315433892, https://openalex.org/W3136587289, https://openalex.org/W3052573234, https://openalex.org/W4281920430, https://openalex.org/W2943853235, https://openalex.org/W2901697104, https://openalex.org/W1891577135, https://openalex.org/W2989290646, https://openalex.org/W2099126386, https://openalex.org/W3119039614, https://openalex.org/W4399663282, https://openalex.org/W2559827832, https://openalex.org/W2131152519, https://openalex.org/W2263073744, https://openalex.org/W2339180622, https://openalex.org/W2995440672, https://openalex.org/W2336509969, https://openalex.org/W2170123390, https://openalex.org/W2128102844, https://openalex.org/W2806365158, https://openalex.org/W3033841996, https://openalex.org/W2070311659, https://openalex.org/W2892910119, https://openalex.org/W2413853065, https://openalex.org/W2938046619, https://openalex.org/W2169083371, https://openalex.org/W2796349932, https://openalex.org/W4398168321, https://openalex.org/W2098394317, https://openalex.org/W2132143019, https://openalex.org/W1978921205, https://openalex.org/W4382023394, https://openalex.org/W2405719380, https://openalex.org/W2494380908, https://openalex.org/W2778954208, https://openalex.org/W4288080931, https://openalex.org/W4200446450, https://openalex.org/W4386484893, https://openalex.org/W4321087997, https://openalex.org/W2136683669, https://openalex.org/W4220662681, https://openalex.org/W2022580424, https://openalex.org/W2735041159, https://openalex.org/W4214602749, https://openalex.org/W4285388802, https://openalex.org/W3004046121, https://openalex.org/W76522298, https://openalex.org/W4220806983, https://openalex.org/W2087025602, https://openalex.org/W2025755104, https://openalex.org/W4312122495, https://openalex.org/W4399861209, https://openalex.org/W1971026939, https://openalex.org/W2161197095, https://openalex.org/W4385330584, https://openalex.org/W4390706808, https://openalex.org/W2079624979, https://openalex.org/W4376279662, https://openalex.org/W2964412249, https://openalex.org/W2009822105, https://openalex.org/W4234854220, https://openalex.org/W3185006436, https://openalex.org/W2079767351, https://openalex.org/W2149360266, https://openalex.org/W4313381117, https://openalex.org/W3138744807, https://openalex.org/W2038074574, https://openalex.org/W4304889239, https://openalex.org/W3207384678, https://openalex.org/W1487745522, https://openalex.org/W4308518331, https://openalex.org/W3215593750, https://openalex.org/W3158278756, https://openalex.org/W2298503769, https://openalex.org/W3011268210, https://openalex.org/W4400487085, https://openalex.org/W4390876398, https://openalex.org/W2057776379, https://openalex.org/W4396552561, https://openalex.org/W2603369913, https://openalex.org/W3094296829, https://openalex.org/W4385729141, https://openalex.org/W2092166052, https://openalex.org/W4387652202, https://openalex.org/W3132255011, https://openalex.org/W4400745991, https://openalex.org/W2810715813, https://openalex.org/W4210261363, https://openalex.org/W3157831753, https://openalex.org/W4383163487, https://openalex.org/W3085221220, https://openalex.org/W2024483330, https://openalex.org/W2994704114, https://openalex.org/W4211227513, https://openalex.org/W2170792469, https://openalex.org/W2140379589, https://openalex.org/W4306843338, https://openalex.org/W2091675007, https://openalex.org/W2981015121, https://openalex.org/W3013979675, https://openalex.org/W4408238872, https://openalex.org/W4390975865, https://openalex.org/W3195696799, https://openalex.org/W4389049606, https://openalex.org/W4386255663, https://openalex.org/W2125439441, https://openalex.org/W2320631874, https://openalex.org/W4392470215, https://openalex.org/W2058475776, https://openalex.org/W3155592118, https://openalex.org/W4389192487, https://openalex.org/W3179022722, https://openalex.org/W4399983639, https://openalex.org/W3217808407, https://openalex.org/W4385620730, https://openalex.org/W2739972212, https://openalex.org/W4389229661, https://openalex.org/W2921016876, https://openalex.org/W2553129782, https://openalex.org/W2171669261, https://openalex.org/W4387731507, https://openalex.org/W2615682320, https://openalex.org/W4401519600, https://openalex.org/W4380029346, https://openalex.org/W4385604541, https://openalex.org/W4313260754, https://openalex.org/W4283801551, https://openalex.org/W4392302767, https://openalex.org/W2003197307, https://openalex.org/W4409245612, https://openalex.org/W3121016072, https://openalex.org/W1954860593, https://openalex.org/W3004241327, https://openalex.org/W4364381898, https://openalex.org/W3004611567, https://openalex.org/W1988852350, https://openalex.org/W2016510876, https://openalex.org/W2111586718, https://openalex.org/W2056315817, https://openalex.org/W4282553073, https://openalex.org/W2980981340, https://openalex.org/W2942874616, https://openalex.org/W2068592123, https://openalex.org/W2652571037, https://openalex.org/W4386707864, https://openalex.org/W4402401857, https://openalex.org/W4316466738, https://openalex.org/W1976681938, https://openalex.org/W2078519876, https://openalex.org/W4297977523, https://openalex.org/W3041641129, https://openalex.org/W4396888660, https://openalex.org/W4396662715, https://openalex.org/W4389453313, https://openalex.org/W4401172046, https://openalex.org/W4310098647, https://openalex.org/W4389233278, https://openalex.org/W4405047725, https://openalex.org/W4310105192, https://openalex.org/W4405034762, https://openalex.org/W4409565465, https://openalex.org/W4400135778, https://openalex.org/W4400098977, https://openalex.org/W4401603883, https://openalex.org/W4310126607, https://openalex.org/W3095958987, https://openalex.org/W1998189366, https://openalex.org/W4226247176, https://openalex.org/W2995447672, https://openalex.org/W4405043131, https://openalex.org/W2987841124, https://openalex.org/W4220824895, https://openalex.org/W2521461373, https://openalex.org/W4220665580, https://openalex.org/W4409078061, https://openalex.org/W1566673803, https://openalex.org/W4387721386, https://openalex.org/W4282599506, https://openalex.org/W3038886185, https://openalex.org/W4368405286, https://openalex.org/W2775982617, https://openalex.org/W2758920466, https://openalex.org/W4220730666, https://openalex.org/W2996286256, https://openalex.org/W3212182291, https://openalex.org/W4362594328, https://openalex.org/W3194228244, https://openalex.org/W4318823516, https://openalex.org/W2945173342, https://openalex.org/W2753012794, https://openalex.org/W4387157895, https://openalex.org/W4280559817, https://openalex.org/W4404993233, https://openalex.org/W4402724009, https://openalex.org/W3130544561, https://openalex.org/W2090083883, https://openalex.org/W2795441690, https://openalex.org/W2981056570, https://openalex.org/W4317401721, https://openalex.org/W2799438446, https://openalex.org/W1555729280, https://openalex.org/W3002644153, https://openalex.org/W4402582248, https://openalex.org/W2081721148, https://openalex.org/W4402277946, https://openalex.org/W3008374051, https://openalex.org/W2980517374, https://openalex.org/W2591761690, https://openalex.org/W2975892120, https://openalex.org/W2754677091, https://openalex.org/W4223562536, https://openalex.org/W2295557285, https://openalex.org/W3152923104, https://openalex.org/W4408717386, https://openalex.org/W4289519058, https://openalex.org/W3022509419, https://openalex.org/W2795256310, https://openalex.org/W2804761342, https://openalex.org/W4403459445, https://openalex.org/W4401856335, https://openalex.org/W2910180594 |
| referenced_works_count | 307 |
| abstract_inverted_index.a | 58, 140 |
| abstract_inverted_index.MM | 26, 110, 127 |
| abstract_inverted_index.NK | 38, 54, 79, 100, 162 |
| abstract_inverted_index.an | 13 |
| abstract_inverted_index.as | 106 |
| abstract_inverted_index.in | 16, 31, 68, 126, 147, 152, 155, 167 |
| abstract_inverted_index.of | 7, 37, 78, 109, 160, 184 |
| abstract_inverted_index.or | 45 |
| abstract_inverted_index.to | 83, 112, 178 |
| abstract_inverted_index.MM. | 65, 192 |
| abstract_inverted_index.and | 35, 102, 154, 182 |
| abstract_inverted_index.are | 4, 43, 175 |
| abstract_inverted_index.but | 123 |
| abstract_inverted_index.for | 63, 120, 188 |
| abstract_inverted_index.has | 128 |
| abstract_inverted_index.its | 124 |
| abstract_inverted_index.may | 56, 91 |
| abstract_inverted_index.the | 8, 33, 76, 94, 107, 158, 180 |
| abstract_inverted_index.who | 42 |
| abstract_inverted_index.(NK) | 2 |
| abstract_inverted_index.This | 88, 132 |
| abstract_inverted_index.been | 129 |
| abstract_inverted_index.both | 32, 151 |
| abstract_inverted_index.cell | 163, 186 |
| abstract_inverted_index.have | 46, 74 |
| abstract_inverted_index.help | 92 |
| abstract_inverted_index.less | 130 |
| abstract_inverted_index.role | 15 |
| abstract_inverted_index.such | 105 |
| abstract_inverted_index.that | 52, 136 |
| abstract_inverted_index.them | 82 |
| abstract_inverted_index.with | 12, 25, 99, 191 |
| abstract_inverted_index.(CAR) | 72 |
| abstract_inverted_index.(MM). | 22 |
| abstract_inverted_index.cells | 3, 55, 101, 111, 138, 146 |
| abstract_inverted_index.evade | 113 |
| abstract_inverted_index.often | 27, 97 |
| abstract_inverted_index.shows | 118 |
| abstract_inverted_index.those | 41 |
| abstract_inverted_index.vitro | 153 |
| abstract_inverted_index.vivo. | 156 |
| abstract_inverted_index.B-cell | 121 |
| abstract_inverted_index.CAR-NK | 116, 137, 185 |
| abstract_inverted_index.Recent | 66 |
| abstract_inverted_index.cells, | 39, 80 |
| abstract_inverted_index.elicit | 139 |
| abstract_inverted_index.escape | 170 |
| abstract_inverted_index.immune | 10, 17, 114, 142 |
| abstract_inverted_index.innate | 9 |
| abstract_inverted_index.killer | 1 |
| abstract_inverted_index.review | 134 |
| abstract_inverted_index.robust | 141 |
| abstract_inverted_index.safety | 183 |
| abstract_inverted_index.system | 11 |
| abstract_inverted_index.target | 84 |
| abstract_inverted_index.trials | 174 |
| abstract_inverted_index.Natural | 0 |
| abstract_inverted_index.ability | 108 |
| abstract_inverted_index.address | 103 |
| abstract_inverted_index.against | 19, 144 |
| abstract_inverted_index.antigen | 70 |
| abstract_inverted_index.exhibit | 28 |
| abstract_inverted_index.myeloma | 21, 145, 169 |
| abstract_inverted_index.promise | 119, 166 |
| abstract_inverted_index.provide | 57 |
| abstract_inverted_index.studies | 149 |
| abstract_inverted_index.therapy | 117, 187 |
| abstract_inverted_index.However, | 23 |
| abstract_inverted_index.Numerous | 172 |
| abstract_inverted_index.allowing | 81 |
| abstract_inverted_index.antigens | 86 |
| abstract_inverted_index.approach | 90 |
| abstract_inverted_index.chimeric | 69 |
| abstract_inverted_index.clinical | 173 |
| abstract_inverted_index.disease. | 48 |
| abstract_inverted_index.dual-CAR | 161 |
| abstract_inverted_index.efficacy | 125, 181 |
| abstract_inverted_index.enhanced | 75 |
| abstract_inverted_index.evaluate | 179 |
| abstract_inverted_index.evidence | 50 |
| abstract_inverted_index.mitigate | 93 |
| abstract_inverted_index.multiple | 20 |
| abstract_inverted_index.patients | 24 |
| abstract_inverted_index.quantity | 34 |
| abstract_inverted_index.receptor | 71 |
| abstract_inverted_index.relapsed | 47 |
| abstract_inverted_index.response | 143 |
| abstract_inverted_index.revealed | 135 |
| abstract_inverted_index.strategy | 62 |
| abstract_inverted_index.suggests | 51 |
| abstract_inverted_index.treating | 64 |
| abstract_inverted_index.underway | 177 |
| abstract_inverted_index.conducted | 150 |
| abstract_inverted_index.currently | 176 |
| abstract_inverted_index.diagnosed | 190 |
| abstract_inverted_index.essential | 14 |
| abstract_inverted_index.examined. | 131 |
| abstract_inverted_index.indicates | 165 |
| abstract_inverted_index.promising | 59 |
| abstract_inverted_index.therapies | 164 |
| abstract_inverted_index.Increasing | 49 |
| abstract_inverted_index.associated | 98 |
| abstract_inverted_index.challenges | 104 |
| abstract_inverted_index.components | 6 |
| abstract_inverted_index.detection. | 115 |
| abstract_inverted_index.harnessing | 53 |
| abstract_inverted_index.innovative | 89 |
| abstract_inverted_index.off-target | 95 |
| abstract_inverted_index.overcoming | 168 |
| abstract_inverted_index.refractory | 44 |
| abstract_inverted_index.toxicities | 96 |
| abstract_inverted_index.development | 159 |
| abstract_inverted_index.engineering | 73 |
| abstract_inverted_index.impairments | 30 |
| abstract_inverted_index.individuals | 189 |
| abstract_inverted_index.mechanisms. | 171 |
| abstract_inverted_index.preclinical | 148 |
| abstract_inverted_index.significant | 29 |
| abstract_inverted_index.specialized | 5 |
| abstract_inverted_index.therapeutic | 61 |
| abstract_inverted_index.Furthermore, | 157 |
| abstract_inverted_index.advancements | 67 |
| abstract_inverted_index.capabilities | 77 |
| abstract_inverted_index.effectively. | 87 |
| abstract_inverted_index.particularly | 40 |
| abstract_inverted_index.surveillance | 18 |
| abstract_inverted_index.MM-associated | 85 |
| abstract_inverted_index.comprehensive | 133 |
| abstract_inverted_index.functionality | 36 |
| abstract_inverted_index.malignancies, | 122 |
| abstract_inverted_index."off-the-shelf" | 60 |
| cited_by_percentile_year | |
| corresponding_author_ids | https://openalex.org/A5101514872 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 3 |
| corresponding_institution_ids | https://openalex.org/I58048189 |
| citation_normalized_percentile |